On Thursday, GSK plc (NYSE:GSK) revealed new preliminary data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) in ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the ...

The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...

Right now, the only RSV vaccine pregnant people can get is the Pfizer vaccine. But there are other vaccines you can get for ...

Nursing home residents with respiratory syncytial virus (RSV) have high risk for illness, frequent hospitalization, and high mortality.

Health officials across Vermont are asking residents to stay safe and prevent the spread of disease by getting updated virus ...

Americans as young as 18 with a chronic condition can now receive an RSV vaccine after Pfizer snagged expanded FDA approval ...

Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...